We used a collection of 9 stem cell models of glioblastoma (HSR-GBM1 [23 (link)]; JHH520 [24 (link)]; NCH421k, NCH644 [25 (link),26 (link)]; BTSC-23, BTSC-233, BTSC-268, BTSC-349, BTSC-407 [27 (link)]), and exposed them to a library of clinical drugs (231 substances, each in 9 different concentrations; 4.33 nM to 25 M) using a semi-automated screening platform. For each cell model, repetitive drug resistance tests were performed: two biological (except for BTSC-23) and three technical replications. For each biological replication, the mean of the technical replications was used. Undifferentiated and immortalized human neural progenitor cells (ReNcell®CX, Sigma-Aldrich, St Louis, MO, USA) and neural stem cells (H9-Derived, Gibco) were used as healthy controls to evaluate the toxicity of the drugs. Additionally, we also tested the inhibition efficiency using three different normal adult human dermal fibroblasts (NHDF-Ad, Lonza, Basel, Switzerland). Effects on cell growth were assessed 72 h after substance exposure using the CellTiterGlow® assay (Promega, Madison, WI, USA). All procedures were in consent with the local ethical commission oversights.
Free full text: Click here
